A new antibiotic drug developed by a research team from the Department of Chemistry at The University of Hong Kong (HKU) has recently gained approval from the authorities to undergo clinical trials in the Mainland.  

The new drug, which has taken the research team ten years to develop and is named Kynomycin, received the "Notice of Approval for Drug Clinical Trials" from the National Medical Products Administration of China to be tested in human subjects.

The new antibiotic drug targets complex skin and soft tissue infections (cSSTI) caused by bacteria. It is a new type of cyclic lipopeptide category 1 drug with a novel chemical structure. The patent is licensed to a pharmaceutical company in the Mainland by HKU’s Technology Transfer Office through the University’s wholly-owned subsidiary, Versitech Limited.

Skin and soft tissue infections are very common bacterial infectious diseases in clinical practice, often leading to emergency visits and hospitalisation. With the emergence of clinically resistant strains and the development of bacterial pathogens that are resistant to antibiotics, treatment options have become increasingly limited.

The development of this drug aims to improve the safety and efficacy of cyclic lipopeptide antibiotics and provide a new choice for clinical treatment. After obtaining approval for this clinical trial, the drug still needs to undergo Phase I, II, and III clinical trials and be evaluated and approved by the National Medical Products Administration before it can be produced and marketed.